[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20191671T1 - Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml) - Google Patents

Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml) Download PDF

Info

Publication number
HRP20191671T1
HRP20191671T1 HRP20191671T HRP20191671T1 HR P20191671 T1 HRP20191671 T1 HR P20191671T1 HR P20191671 T HRP20191671 T HR P20191671T HR P20191671 T1 HRP20191671 T1 HR P20191671T1
Authority
HR
Croatia
Prior art keywords
peptide
antibody
fusion protein
cell
host cell
Prior art date
Application number
Other languages
English (en)
Inventor
Juliane Walz
Daniel Kowalewski
Claudia Berlin
Hans-Georg Rammensee
Stefan Stevanovic
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1408255.6A external-priority patent/GB201408255D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of HRP20191671T1 publication Critical patent/HRP20191671T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04004—Plus-end-directed kinesin ATPase (3.6.4.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y599/00—Other isomerases (5.99)
    • C12Y599/01—Other isomerases (5.99.1)
    • C12Y599/01002—DNA topoisomerase (5.99.1.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Claims (15)

1. Peptid dužine od između 9 i 30 aminokiselina, koji se sastoji od aminokiselinske sekvence KLQEQLAQL u skladu s ID br. SEKV 266, ili farmaceutski prihvatljive soli istog.
2. Peptid u skladu s patentnim zahtjevom 1, naznačen time što je navedeni peptid modificiran i/ili uključuje nepeptidne veze.
3. T-stanični receptor koji je reaktivan s HLA ligandom koji ima najmanje 80% identiteta aminokiselinske sekvence u skladu s ID br. SEKV 266.
4. Fuzijski protein, koji sadrži aminokiselinsku sekvencu u skladu s patentnim zahtjevom 1, koji je fuzioniran u N-terminalne aminokiseline 1-80 HLA-DR invarijantnog lanca vezanog za antigene (Ii) ili fuzioniranog na ili u sekvencu antitijela, kao što je, na primjer, antitijelo koje je specifično za dendritične stanice.
5. Antitijelo koje se specifično vezuje za molekulu humanog glavnog kompleksa gena tkivne podudarnosti (MHC) klase I koji se sjedinjuje s peptidom u skladu s patentnim zahtjevom 1 ili 2.
6. Nukleinska kiselina, koja kodira peptid u skladu s patentnim zahtjevom 1 ili 2, T-stanični receptor u skladu s patentnim zahtjevom 3, fuzijski protein u skladu s patentnim zahtjevom 4, ili antitijelo u skladu s patentnim zahtjevom 5.
7. Vektor ekspresije koji eksprimira nukleinsku kiselinu u skladu s patentnim zahtjevom 6.
8. Stanica domaćin koja se sastoji od nukleinske kiseline u skladu s patentnim zahtjevom 6, ili vektor ekspresije u skladu s patentnim zahtjevom 7, pri čemu je navedena stanica domaćin poželjno antigen prezentirajuća stanica, na primjer dendritična stanica.
9. Metoda za proizvodnju peptida u skladu s patentnim zahtjevom 1 ili 2, T-stanični receptor u skladu s patentnim zahtjevom 3, fuzijski protein u skladu s patentnim zahtjevom 4, ili antitijelo u skladu s patentnim zahtjevom 5, navedena metoda sastoji se od kultiviranja stanice domaćina u skladu s patentnim zahtjevom 8, i izoliranjem navedenog peptida, navedenog T-staničnog receptora, navedenog fuzijskog proteina ili navedenog antibtijela iz navedene stanice domaćina i/ili njihovog medija za kultiviranje.
10. In vitro metoda za proizvodnju aktiviranih citotoksičnih T limfocita (CTL), metoda koja se sastoji od dovođenja u kontakt in vitro CTL s humanim MHC molekulama klase I s ubačenim antigenom eksprimiranim na površini prikladne antigen-prezentirajuće stanice tijekom vremenskog razdoblja koji je dovoljan da se navedeni CTL aktiviraju na antigen-specifičan način, pri čemu je navedeni antigen navedeni peptid u skladu s patentnim zahtjevom 1 ili 2.
11. Aktivirani citotoksični T limfocit (CTL), proizveden metodom u skladu s patentnim zahtjevom 10, i specifičan za peptid patentnog zahtjeva 1 ili 2.
12. Farmaceutska smjesa, koja se sastoji od peptida u skladu s patentnim zahtjevom 1 ili 2, T-stanični receptor u skladu s patentnim zahtjevom 3, fuzijski protein u skladu s patentnim zahtjevom 4, antitijelo u skladu s patentnim zahtjevom 5, nukleinska kiselina u skladu s patentnim zahtjevom 6, ili vektor ekspresije u skladu s patentnim zahtjevom 7, stanica domaćina u skladu s patentnim zahtjevom 8, ili aktivirani citotoksični T limfocit u skladu s patentnim zahtjevom 11, i farmaceutski prihvatljivi nosač, pri čemu je navedena farmaceutska smjesa poželjno vakcina.
13. Peptid u skladu s patentnim zahtjevom 1 ili 2, T-stanični receptor u skladu s patentnim zahtjevom 3, fuzijski protein u skladu s patentnim zahtjevom 4, antibtijelo u skladu s patentnim zahtjevom 5, nukleinska kiselina u skladu s patentnim zahtjevom 6, vektor ekspresije u skladu s patentnim zahtjevom 7, stanica domaćin u skladu s patentnim zahtjevom 8, aktivirani citotoksični T limfocit u skladu s patentnim zahtjevom 11 ili farmaceutska smjesa u skladu s patentnim zahtjevom 12 za upotrebu u medicini.
14. Peptid u skladu s patentnim zahtjevom 1 ili 2, T-stanični receptor u skladu s patentnim zahtjevom 3, fuzijski protein u skladu s patentnim zahtjevom 4, antitijelo u skladu s patentnim zahtjevom 5, nukleinsku kiselina u skladu s patentnim zahtjevom 6, vektor ekspresije u skladu s patentnim zahtjevom 7, stanica domaćin u skladu s patentnim zahtjevom 8, aktivirani citotoksični T limfocit u skladu s patentnim zahtjevom 11 ili farmaceutska smjesa u skladu s patentnim zahtjevom 12 za upotrebu u terapiji raka.
15. Upotreba u skladu s patentnim zahtjevom 14, pri čemu je navedeni rak akutna mijeloična leukemija i/ili kronična limfatična leukemija, rak jetre ili rak debelog crijeva.
HRP20191671 2014-05-09 2019-09-17 Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml) HRP20191671T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461990980P 2014-05-09 2014-05-09
GBGB1408255.6A GB201408255D0 (en) 2014-05-09 2014-05-09 Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
PCT/EP2015/060168 WO2015169945A2 (en) 2014-05-09 2015-05-08 Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
EP15732544.0A EP3140319B1 (en) 2014-05-09 2015-05-08 Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)

Publications (1)

Publication Number Publication Date
HRP20191671T1 true HRP20191671T1 (hr) 2019-12-13

Family

ID=59009437

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191671 HRP20191671T1 (hr) 2014-05-09 2019-09-17 Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)

Country Status (7)

Country Link
US (6) US10525115B2 (hr)
CY (1) CY1122083T1 (hr)
HK (1) HK1232240A1 (hr)
HR (1) HRP20191671T1 (hr)
IL (2) IL248203A0 (hr)
MX (1) MX2019013163A (hr)
PH (1) PH12016502008A1 (hr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
EP4368189A1 (en) * 2022-11-09 2024-05-15 Eberhard Karls Universität Tübingen, Medizinische Fakultät Peptides and combinations of peptides for use in immunotherapy against acute myeloid leukemia (aml) and other hematological neoplasms

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016174A2 (en) 1999-08-30 2001-03-08 Rolf Kiessling Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopes of mycobacterial heat shock protein 65
AU2001249345A1 (en) 2000-03-21 2001-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
KR100692416B1 (ko) 2003-05-26 2007-03-09 학교법인 배재학당 Ｆａｆ1 단편 및 그를 함유하는 종양 전이 억제제
US20050261190A1 (en) 2004-04-29 2005-11-24 Sk Corp. Fas associated factor 1
US7314630B2 (en) 2005-01-07 2008-01-01 Yao-Xiong Hu Compounds and methods of early diagnosis of cervical cancer and genital condyloma with HPV, CHSP60 tumor suppressor H-Ras, K-Ras and PTEN derived peptides modified
PT1806359E (pt) 2005-09-05 2010-05-25 Immatics Biotechnologies Gmbh Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
AU2008281014B2 (en) 2007-07-27 2012-06-28 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy

Also Published As

Publication number Publication date
US10668137B2 (en) 2020-06-02
HK1232240A1 (zh) 2018-01-05
US20210008189A1 (en) 2021-01-14
IL271367A (en) 2020-01-30
US10525115B2 (en) 2020-01-07
US20200268862A1 (en) 2020-08-27
US20190275130A1 (en) 2019-09-12
PH12016502008A1 (en) 2017-02-06
US20210023189A1 (en) 2021-01-28
CY1122083T1 (el) 2020-11-25
US10813985B2 (en) 2020-10-27
US20200093905A1 (en) 2020-03-26
MX2019013163A (es) 2020-02-05
IL248203A0 (en) 2016-11-30
US10898562B1 (en) 2021-01-26
US20200254078A1 (en) 2020-08-13
US10925949B2 (en) 2021-02-23
US10799571B2 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
HRP20202019T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
HRP20210709T1 (hr) Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma
HRP20201467T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
HRP20210698T1 (hr) Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
HRP20192262T1 (hr) Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc)
HRP20201228T1 (hr) Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20201281T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma
AR121383A2 (es) Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
EA201892021A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
EA201891759A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
PH12018501933A1 (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
HRP20230512T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma
JP2013521789A5 (hr)
PH12018501892A1 (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
HRP20230878T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raznih karcinoma (seq id 25 - mrax5-003)
PE20240778A1 (es) Nuevos peptidos y combinacion de peptidos para usar en inmuterapia contra el cancer esofagico y otros canceres
HRP20191671T1 (hr) Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
HRP20240359T1 (hr) Peptidi iz piwil1
HRP20200967T1 (hr) Nova imunoterapija protiv nekoliko tumora krvi, posebice kronične limfoidne leukemije (cll)
HRP20210528T1 (hr) Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma
HRP20211580T1 (hr) Novi peptidi i kombinacije peptida za upotrebu u imunoterpiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
AR122383A2 (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
AR106499A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón microcítico y otros tipos de cáncer
TH1701005356A (th) เพปไทด์ชนิดใหม่และการรวมกันของเพปไทด์สำหรับใช้ในการบำบัดด้วยภูมิคุ้มกัน ต่อมะเร็งตับอ่อนและมะเร็งอื่น